quarter of 2011. Premier is a hospital-based health care utilization database that contains administrative codes for discharge diagnoses based on the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The Premier database also contains detailed information on all charges for procedures, medications, blood products, and laboratory and radiologic diagnostic tests performed during inpatient hospitalizations. The database has been used extensively in prior studies to evaluate the patterns of use and safety of inpatient medications. [12] [13] [14] [15] [16] [17] The use of this database for research was approved by the Partners IRB (Boston, MA).
Cohort
Using a modified version of the algorithm described by Kuklina et al. 18 that uses diagnosis and procedure codes from the ICD-9-CM, we identified inpatient admissions with diagnosis or procedure codes indicating delivery (Supplemental Digital Content 1, http://links.lww.com/ AA/A978). We excluded hospitalizations with any codes indicating abortion, ectopic pregnancy, hydatidiform mole, or other abnormal products of conception. Because we were specifically interested in hospital-level rates of second-line uterotonic administration, we restricted our analysis to hospitals with >100 deliveries in the database (because smaller numbers of deliveries would yield unstable estimates of second-line uterotonic use) and with at least 1 patient charged for a second-line uterotonic (to exclude hospitals in which uterotonic administration may not be reliably coded). This resulted in the exclusion of 14 and 12 hospitals, respectively. The final cohort included 367 hospitals.
Exposure
The Premier database contains charge codes that can be used to identify drugs administered during a hospital admission. In this study, these charge codes were used to identify second-line uterotonics (methylergonovine maleate, carboprost, or misoprostol) that were used during the hospitalization for delivery. Because misoprostol at low doses (i.e., oral 50 μg or intravaginal 25 μg to a cumulative dose <250 μg) can also be used as an induction drug, 19 we considered misoprostol as a second-line uterotonic only if the total dose was in excess of 400 μg and if the patient did not have an ICD-9-CM procedure code indicating medical induction of labor.
Covariates
We considered 5 groups of covariates which might act as risk factors for uterine atony and thus account for variation in the use of second-line uterotonics: (1) patient demographics, (2) year of delivery, (3) mode of delivery, (4) medical and obstetrical conditions, and (5) hospital characteristics. We assessed the following patient demographics: maternal age (categorized as <20, 20-24, 25-29, 30-34, 35-39, 40-44, 45-55 years; categorized to avoid the assumption of monotonicity between age and model logits) and race/ethnicity (categorized as non-Hispanic Caucasian, non-Hispanic African American, Hispanic, and other/unknown). Mode of delivery was defined as vaginal versus cesarean and induced or noninduced, both of which were defined by ICD-9-CM procedure codes (Supplemental Digital Content 2, http://links.lww.com/AA/A979). Medical and obstetrical conditions that might act as risk factors for atony were defined based on the presence of ICD-9-CM diagnosis codes during the delivery hospitalization and included preexisting hypertension, gestational hypertension, preeclampsia/ eclampsia, preexisting diabetes, gestational diabetes, preterm delivery, obesity, polyhydramnios, abnormal placentation including placenta previa, placental abruption, previous cesarean delivery, stillbirth, multiple gestations, and chorioamnionitis (Supplemental Digital Content 2, http://links. lww.com/AA/A979). We assessed the following delivery hospital characteristics (recorded directly in the database): teaching status, urban (versus rural) location, geographic region (categorized as Midwest, Northeast, South, and West), and annual delivery volume tertile (which divides the hospitals into 3 equally sized groups, based on delivery volume, categorized as low, medium, or high, which corresponds to thresholds of <814 deliveries, 814-1892 deliveries, and >1892 deliveries, respectively).
Statistical Analysis
The proportion of patients admitted for delivery who received methylergonovine maleate, carboprost, or misoprostol was determined for each hospital. The mean, median, and interquartile range for overall use of secondline uterotonic and individual second-line uterotonic use were reported. Hospitals were divided into quartiles based on the overall proportion of patients who received 1 or more second-line uterotonics. Baseline patient and hospital characteristics that were likely to influence the use of secondline uterotonics were described, 1, 16, [20] [21] [22] stratified by hospital quartile, and compared with a χ 2 test.
Mixed-effects logistic regression models were used to estimate the hospital-specific frequency of second-line uterotonic use adjusting for the case mix of patients and hospital characteristics, accounting for random variation. In these models, a variable identifying each hospital was included as a normally distributed random intercept, and demographic, obstetrical, and hospital-level covariates were modeled as fixed effects. The hospital-specific intercept represents the hospital-specific frequency for second-line uterotonic use after adjusting for patient and hospital characteristics.
We used sequential mixed effects models to assess the relative influence of different patient and hospital characteristics for between-hospital variation in second-line uterotonic use. We constructed sequential models with increasing levels of adjustment to account for the following sets of covariates: (model 1) patient demographics, (model 2) demographics and year of delivery, (model 3) demographics, year of delivery, and method/mode of delivery, (model 4) demographics, year of delivery, method/ mode of delivery, and medical/obstetrical conditions, and (model 5) demographics, year of delivery, method/mode of delivery, medical/obstetrical conditions, and hospital characteristics. After adjusting for all of these patient-and hospital-level characteristics, the hospital-specific intercepts represent the "intrinsic" hospital-level tendency to use second-line uterotonics independent of measured patient-and hospital-level factors.
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Second-Line Uterotonic Use in the United States Because of the large number of patient-and hospitallevel factors, we used propensity scores as a data reduction technique at each stage of sequential adjustment. 23 For each of the 5 sequential models, a separate propensity score was estimated to predict exposure to a second-line uterotonic.
The propensity score was centered on the mean such that the random intercept for each hospital represents the probability that an average patient (defined as patient with a propensity score at the mean) would be treated with a second-line uterotonic in a given hospital. Additional details Data presented as percentages.
Any uterotonic refers to the use of at least 1 of the following uterotonic drugs: methylergonovine maleate, carboprost, misoprostol. 
RESULTS
The cohort included 2,180,916 patients hospitalized for delivery at any 1 of 367 hospitals. The median hospital level frequency of second-line uterotonic use was 7.1% (interquartile range 5.2% to 10.8%). The median hospital level frequency of methylergonovine maleate use was 5.2%, carboprost 1.0%, and misoprostol 1.2% (Table 1) . We stratified hospitals into quartiles based on the proportion of patients treated with 1 or more second-line uterotonics (Table 2 ). There were significant differences among hospital quartiles in all of the covariates assessed (P < 0.01), with the exception of stillbirth (P = 0.55) and gestational diabetes (P = 0.09).
The results of the 5 sequential mixed-effects logistic regression models with demographic, medical, obstetrical, and hospital-level covariates added at each step are shown in Table 3 (β coefficients and P values for each of the propensity score models and measures of model calibration shown in Supplemental Digital Content Tables 1 and 2 , Supplemental Digital Content 4, http://links.lww.com/ AA/A981). The between-hospital variance in the use of second-line uterotonics is described by σ b 2 . The mean predicted probability of exposure to a second-line uterotonic and the 2.5th to 97.5th percentile is also displayed. If the between-hospital variation in second-line uterotonic use is fully explained by the covariates in the model, σ b 2 would be expected to approach zero and all hospitals would be predicted to have the same probability of second-line uterotonic use. In the unadjusted model, the σ b 2 (SE) was 0.61 (0.05); the mean (SE) probability of exposure to secondline uterotonics was 7.30% (0.28%) and 95% of the hospitals had a predicted probability between 1.69% (0.12%) and 26.58% (1.37%). These estimates remove random variation compared with the crude estimates, but do not account for potential between-hospital differences in patient and hospital characteristics. In the fully adjusted model (model 5), the σ b 2 decreased slightly to 0.57 (0.04). The mean predicted probability was 7.02% (0.26%), with 95% of the hospitals having a predicted probability between 1.69% (0.12%) and Estimate of the between-hospital variation. The random intercept b j is assumed to be normally distributed with mean 0 and variance σ b 2 . σ b 2 represents the hospital-specific deviation from β 0 , the marginal (averaged across hospitals) probability of using a second-line uterotonic for a patient with the mean propensity score. With increasing levels of adjustment, there is less unexplained variation and σ b 2 is expected to decrease. 
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Second-Line Uterotonic Use in the United States 24.96% (1.28%). The predicted probabilities of second-line uterotonic use for each hospital in rank-order in the unadjusted and fully adjusted models are presented in Figure 1 .
We observed little attenuation of the variation in use of these drugs when accounting for a broad range of patient and hospital characteristics.
DISCUSSION
In this large, nationwide sample of delivery admissions in the United States, we observed significant variability in the frequency of second-line uterotonic use. Adjustment for patient demographics, mode of delivery, medical and obstetrical conditions, year of delivery, and hospital characteristics did little to explain this variation in practice, with the frequency of second-line uterotonic use ranging from 1.7% to 25% in the fully adjusted model. These findings suggest that the frequency of second-line uterotonic use is largely based on nonmedical and institution-specific factors, such as individual physician preferences, uterotonic drug availability, drug cost, and local hospital culture. There has been a substantial increase in the incidence of atonic hemorrhage, including severe atonic hemorrhage requiring transfusion and/or hysterectomy, in a number of developed countries. 1, [5] [6] [7] [8] In addition, hemorrhage remains a leading cause of maternal morbidity 24 and mortality 2 in the United States. As a consequence, there is a need to optimize preventive and therapeutic clinical practices in order to reduce rates of atonic PPH. We observed wide variability in the rates of second-line uterotonic use, which may be related to the limited data regarding the relative effectiveness or timing of administration of these drugs. Studies to address these evidence gaps are needed to ascertain optimal pharmacologic approaches for managing patients with uterine atony. This research should be made an important priority within the field of obstetrics, especially as rates of uterine atonic PPH are increasing.
This study is subject to certain limitations inherent in its design. This study was not able to examine the association between uterotonic drug use and postpartum blood loss or the time to achievement of adequate uterine tone; these data are not available in the Premier database. Future prospective studies are needed to evaluate and define the indications for second-line uterotonic use and to determine whether their dose or timing is associated with less hemorrhage-related morbidity due to uterine atony. Because the database does not include the indications for which a medication was administered, we made the assumption that misoprostol was not being used as a treatment for uterine atony if administered at low doses or in patients with procedure codes indicating induction of labor; this may have led to an underestimation of the frequency of misoprostol use as a second-line uterotonic. We do not have information on the dose or timing of prophylactic oxytocin given before second-line uterotonic use, nor do we have information about the use of supplemental oxytocin. Identification of patient comorbidities and obstetrical conditions that may be potential explanatory variables was based on ICD-9-CM codes. For some conditions, such as obesity, the sensitivity of the ICD-9-CM codes is limited and some potentially relevant risk factors for PPH (e.g., history of PPH, birth weight) do not have corresponding codes. Although these limitations may lead us to underestimate the extent to which patient-and hospital-level covariates explain the variation in second-line uterotonic use, it is very unlikely to fully explain the significant interhospital differences that we report.
In summary, using a nationwide dataset, we observed wide interhospital variation in second-line uterotonic use that was not explained by patient-or hospital-level characteristics. With rates of atonic PPH steadily increasing in the United States, greater emphasis should be placed on defining optimal pharmacologic strategies for the management of uterine atony and on investigating hospital-and provider-level factors to explain the wide variation in secondline uterotonic use. E
